Your browser doesn't support javascript.
loading
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Montgomery, Hugh; Hobbs, F D Richard; Padilla, Francisco; Arbetter, Douglas; Templeton, Alison; Seegobin, Seth; Kim, Kenneth; Campos, Jesus Abraham Simón; Arends, Rosalinda H; Brodek, Bryan H; Brooks, Dennis; Garbes, Pedro; Jimenez, Julieta; Koh, Gavin C K W; Padilla, Kelly W; Streicher, Katie; Viani, Rolando M; Alagappan, Vijay; Pangalos, Menelas N; Esser, Mark T.
Afiliação
  • Montgomery H; Department of Medicine, University College London, London, UK.
  • Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Padilla F; Centro de Investigación en Cardiología y Metabolismo, Guadalajara, Jalisco, Mexico.
  • Arbetter D; Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Boston, MA, USA.
  • Templeton A; Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.
  • Seegobin S; Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.
  • Kim K; ARK Clinical Research, Long Beach, CA, USA.
  • Campos JAS; Köhler & Milstein Research/Hospital Agustín O'Horán, Mérida, Yucatán, Mexico.
  • Arends RH; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.
  • Brodek BH; Development Operations, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Brooks D; Patient Safety, Chief Medical Office, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Garbes P; Clinical Pharmacology and Quantitative Pharmacology, Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Jimenez J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Koh GCKW; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.
  • Padilla KW; Clinical Development, Late-stage Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC, USA.
  • Streicher K; Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Viani RM; Clinical Pharmacology and Quantitative Pharmacology, Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Alagappan V; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Pangalos MN; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.
  • Esser MT; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: mark.esser@astrazeneca.com.
Lancet Respir Med ; 10(10): 985-996, 2022 10.
Article em En | MEDLINE | ID: mdl-35688164
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article